Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 NXHQW2sySXCxcITvd4l{KEG|c3H5 Mn;4N|AwQDBxMUWwM|I2OCCwTR?= NHOxbJEzPC92OD:3NkBp M2LZPIlv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> M4fYXVI2QDh{NUWw
MV411 M3XIbmFxd3C2b4Ppd{BCe3OjeR?= MYWzNE85OC9zNUCvNlUxKG6P MUGyOE81QC95MjDo M4D0R4lv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> NV[4S2tFOjV6OEK1OVA>
MGC-803 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVXtd2lKOC5zLUGwNFAhdk1? NGr6OlE4OiCq MmHObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MYWyOVU6ODhyNR?=
SGC-7901 M{n4U2NmdGxiVnnhZoltcXS7IFHzd4F6 M{HJZlAvOS1zMECwJI5O NVLmVIhpPzJiaB?= M2TyZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYOyOVU6ODhyNR?=
MKN-28 NYrQfpRUS2WubDDWbYFjcWyrdImgRZN{[Xl? NH\SWW8xNjFvMUCwNEBvVQ>? M4PJ[lczKGh? NHnFd3ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXrHfmpEOjV3OUC4NFU>
MGC-803 NYfXNWVNTnWwY4Tpc44hSXO|YYm= NXq4fWZxOC5zLUGwNFAhdk1? MoHjNlQhcA>? NEP0[5dqdmS3Y3XzJGczN01iY3XscE1kgWOuZTDhdpJme3R? NHrCfVkzPTV7MEiwOS=>
HCT-116 MVjGeY5kfGmxbjDBd5NigQ>? MknuOVBvVQ>? M3znflI1KGh? MkPqSG1UVw>? NXfOZ3F1cW6mdXPl[EBIOC:JMTDhdpJme3R? NWjzfHFIOjV{MUC3PVQ>
HT-29 Mn\iSpVv[3Srb36gRZN{[Xl? MUm1NI5O MmXXNlQhcA>? MVHEUXNQ MUPpcoR2[2WmIFewM2cyKGG{cnXzeC=> MnXmNlUzOTB5OUS=
SCC25 NUXMb3dQS3m2b4jpZ4l1gSCDc4PhfS=> NYraXFV2OTBxNUCgcm0> NVXBS|NrOjRiaB?= NGTxXZRl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NYLxS2RCOjV{MEW0N|A>
FUDA M2\neGN6fG:6aXPpeJkhSXO|YYm= NHTTdXkyOC93MDDuUS=> M3:xV|I1KGh? MVXk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= MUOyOVIxPTR|MB?=
Detroit562 M2i5V2N6fG:6aXPpeJkhSXO|YYm= NXniPHJ7OTBxNUCgcm0> MX6yOEBp NXHTN5lM\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NULufJhSOjV{MEW0N|A>
CAL27 NXvLUmVxS3m2b4jpZ4l1gSCDc4PhfS=> NGnEblYyOC93MDDuUS=> NUjYVJIxOjRiaB?= NVn2bJdH\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 Mkn4NlUzODV2M{C=
DSH1 NXPJfVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxWIFJUUN3ME22JI5O MV2yOFc5PDh|OR?=
SW-1710 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTZibl2= M3SxclI1Pzh2OEO5
T24 M3fqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhR3pyUUN3ME23JI5O NGG0OGEzPDd6NEizPS=>
RT112 NHHkWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD17IH7N Ml\BNlQ4QDR6M{m=
639-V NXjB[ZVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3UUplKSzVyPUGwJI5O NFXiO4szPDd6NEizPS=>
SCaBER MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFyIH7N NF2zNXYzPDd6NEizPS=>
BFTC Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF5IH7N M{XvUlI1Pzh2OEO5
J82 NVfNWJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO2TWM2OD1zODDuUS=> Ml3uNlQ4QDR6M{m=
HT-1376 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJzIH7N Mo\WNlQ4QDR6M{m=
647-V NEPsVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ5IH7N NU\mNVBKOjR5OES4N|k>
UM-UC3 NVnKN5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHvOmhnUUN3ME2zN{BvVQ>? NIjXSGwzPDd6NEizPS=>
LB831-BLC NWLrSG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjYdnFKSzVyPUO0JI5O NHvaW|EzPDd6NEizPS=>
KU-19-19 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LtRmlEPTB;M{[gcm0> M2H4b|I1Pzh2OEO5
35612 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH5PItWUUN3ME2zPEBvVQ>? MWWyOFc5PDh|OR?=
5637 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR2IH7N M4m4WFI1Pzh2OEO5
HT-1197 M3zMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTV|IH7N M3jIUVI1Pzh2OEO5
MGH-U3 NIe2NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\RXGlEPTB;NUOgcm0> MW[yOFc5PDh|OR?=
TCCSUP NXn1UHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTBOotKSzVyPUG0NkBvVQ>? MYWyOFc5PDh|OR?=
RT4 NFLMWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3nTIxVUUN3ME2xO|M{KG6P NILFfXozPDd6NEizPS=>
SW780 M1TUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\JW3FKSzVyPUO0OVEhdk1? NYrXZnZ3OjR5OES4N|k>
RKO M1\W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPoU2pMUUN3ME20JI5O MmPsNlQ3QDJ5NEe=
LS-411 N M2TheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVibl2= MW[yOFY5Ojd2Nx?=
SW620 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X1SWlEPTB;ODDuUS=> M{nGeFI1Pjh{N{S3
HCT-15 NFnORo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y4PWlEPTB;ODDuUS=> M1\4bVI1Pjh{N{S3
HuTu-80 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnwfYJKSzVyPUGzJI5O MXSyOFY5Ojd2Nx?=
HCT 116 NWL4RWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrzOW12UUN3ME2xOEBvVQ>? MnnHNlQ3QDJ5NEe=
COLO-205 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\mOXB1UUN3ME2xOEBvVQ>? MXOyOFY5Ojd2Nx?=
NCI-H747 M4fJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmze3ZoUUN3ME2xO{BvVQ>? MXKyOFY5Ojd2Nx?=
COLO-678 NU\lZoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq4TWM2OD1{MTDuUS=> MoHnNlQ3QDJ5NEe=
LoVo Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXjdpIxUUN3ME2yNkBvVQ>? M3jVd|I1Pjh{N{S3
LS-1034 NXjGeIRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jXOmlEPTB;M{Ggcm0> NXy0bWFDOjR4OEK3OFc>
SNU-C2B NYT6XFBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrpTWM2OD12NTDuUS=> MkH0NlQ3QDJ5NEe=
LS-123 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLrOGxKSzVyPUezJI5O NXPZbFlLOjR4OEK3OFc>
SK-CO-1 M2DkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEV5MxUUN3ME24NUBvVQ>? M3H6TFI1Pjh{N{S3
HCC2998 M17Be2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF{ODDuUS=> NU\SeGhuOjR4OEK3OFc>
MDA-MB-231 NEPofWVHfW6ldHnvckBCe3OjeR?= NHzwRlAyODBibl2= MlPjN|AhdWmw NFPqXVBqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= NID4OVUzPDJ2OEK2OS=>
MDA-MB-435 NGPzXnZHfW6ldHnvckBCe3OjeR?= M2DYVVExOCCwTR?= NI[zS5Y{OCCvaX6= NE\HeIlqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= MUiyOFI1QDJ4NR?=
BT-20  NELzSGtHfW6ldHnvckBCe3OjeR?= Mn7ZNVAxNzJ3MDDuUS=> M2m3NFI1KGh? NXjvZ3hCemW|dXz0[YQhcW5iYTDkc5NmNWSncHXu[IVvfCCmZYP0ZYJqdGm8YYTpc44hd2ZiRVfGVkwhUUeILVnSMEBOTVRuIHHu[EBEWkGI Mn;PNlQyPzN3NEG=
MDA-MB-231 NXjNdlhSTnWwY4Tpc44hSXO|YYm= M3TnVlExOCCwTR?= NWrrcWdqOjRiaB?= NGjQSIVqdmirYnn0d{B1cGVibXnndoF1d3K7IHHu[EBqdn[jc3n2[UBk[XCjY3n0feKh NIjvcIYzPDF5M{W0NS=>
H82 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNyLkK3JI5O MU[yOFE3PjVyNR?=
GLC4 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJyLkS3JI5O Mk\jNlQyPjZ3MEW=
H69 NYLBXIloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlywTWM2OD16Mz6zOkBvVQ>? MnHTNlQyPjZ3MEW=
H128 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2XGlEPTB;NkmuOVUhdk1? NXTOcHZnOjRzNk[1NFU>
H146 NVzZ[nVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jURmlEPTB;MkiuOVEhdk1? NV7nVFl2OjRzNk[1NFU>
H187 NF3BbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD1{ND65PUBvVQ>? M3q5ZlI1OTZ4NUC1
H526 NUfETFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHyOpVKSzVyPUKxMlY1KG6P MYKyOFE3PjVyNR?=
N592 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPJWI9KSzVyPUG0MlEzKG6P NVfQT2FDOjRzNk[1NFU>
H620 NYrueFVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN{Lk[3JI5O NHe3c3QzPDF4NkWwOS=>
H792 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTR3LkC3JI5O NXWxO4pYOjRzNk[1NFU>
H1173 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2W3pKSzVyPUGyMlYzKG6P MlzyNlQyPjZ3MEW=
AC3 M17ZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWxZpFKSzVyPUK1Mlkhdk1? NXuyR5RsOjRzNk[1NFU>
H82 M1HkPWZ2dmO2aX;uJGF{e2G7 NXzzZW9sOzBibl2= MlrMO|IhcA>? M2rkPIlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> NXrFUHk{OjRzNk[1NFU>
GLC4 MlS2SpVv[3Srb36gRZN{[Xl? MnvsN|Ahdk1? NEDYWHo4OiCq NUjvcIRwcW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 NYnCPI9nOjRzNk[1NFU>
H146  M2r6TGZ2dmO2aX;uJGF{e2G7 M4nyPFMxKG6P NXLSV4lWPzJiaB?= NVXjRWE6cW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 M3LU[|I1OTZ4NUC1
OVCAR-5 NGS4OYNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2LlbVAuOTByMDDuUS=> NGjuXZM4OiCq MkDwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEn4NIMzOzlyMEGzOi=>
OVCAR-8 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFLlSmcxNTFyMECgcm0> NFvvbnY4OiCq Mo\ibY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHnzU2kzOzlyMEGzOi=>
A1847 M4\rcGNmdGxiVnnhZoltcXS7IFHzd4F6 M2f3b|AuOTByMDDuUS=> MUW3NkBp MmXvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MkXmNlM6ODBzM{[=
SKOV-3 NVj3fXY4S2WubDDWbYFjcWyrdImgRZN{[Xl? NHzmbJMxNTFyMECgcm0> M4\2b|czKGh? M17obolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MoCwNlM6ODBzM{[=
OVCAR-5 M3fQXmFxd3C2b4Ppd{BCe3OjeR?= NUnUeJJzOTBvMUCwJI5O MUOyOE81QC95MjDo NF3UNWdqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 MV[yN|kxODF|Nh?=
OVCAR-8 NFj3cJFCeG:ydH;zbZMhSXO|YYm= MkHVNVAuOTByIH7N NH3rOJozPC92OD:3NkBp NWe2WJd6cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> NI\NVo8zOzlyMEGzOi=>
A1847 NGfWRnhCeG:ydH;zbZMhSXO|YYm= MVGxNE0yODBibl2= NH\yS5IzPC92OD:3NkBp NUTzUJpmcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> MmGyNlM6ODBzM{[=
H2228 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MViwMVExODBibl2= NXzxRmp5PzJiaB?= NUHXOmdIUUN3ME2xN{BvVQ>? MX[yN|U{OzJ4NR?=
H3122 Mk\RR4VtdCCYaXHibYxqfHliQYPzZZk> M4KxTlAuOTByMDDuUS=> M1XFUlczKGh? MkDqTWM2OD1zMDDuUS=> M2fqZlI{PTN|Mk[1
K008 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHTDdXFKSzVyPU[wJI5O MYWyN|QyQDV{Mx?=
K028 M4rCW2NmdGxiVnnhZoltcXS7IFHzd4F6 MoDhTWM2OD16NDDuUS=> NWfHW|d5OjN2MUi1NlM>
K029 M4T0UmNmdGxiVnnhZoltcXS7IFHzd4F6 NUXQRYg2UUN3ME20OkBvVQ>? NETrVHgzOzRzOEWyNy=>
M23 M{XMUWNmdGxiVnnhZoltcXS7IFHzd4F6 MX\JR|UxRTN5LkWgcm0> NGXVVIkzOzRzOEWyNy=>
K033 NIf1Z3NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1HWZmlEPTB;N{WuOUBvVQ>? NVvYR3hYOjN2MUi1NlM>
K008 NIP6cndHfW6ldHnvckBCe3OjeR?= NUjlPIpSOjVyIH7N MVeyOEBp NIr3c4RqdmS3Y3XzJGczKGG{cnXzeC=> NXHqNIdEOjN2MUi1NlM>
K028 MkXaSpVv[3Srb36gRZN{[Xl? NVrIPGs6OjVyIH7N M2SxPFI1KGh? NWHZfIsycW6mdXPld{BIOiCjcoLld5Q> M{mwSFI{PDF6NUKz
K029 MoTDSpVv[3Srb36gRZN{[Xl? M1HwXlI2OCCwTR?= NETXZmkzPCCq M4fHZ4lv\HWlZYOgS|Eh[XK{ZYP0 NFH3cGozOzRzOEWyNy=>
M23 NWHxUFJDTnWwY4Tpc44hSXO|YYm= NEjsU4YzPTBibl2= MVGyOEBp MnPTbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= MkXiNlM1OTh3MkO=
K033 MUHGeY5kfGmxbjDBd5NigQ>? NHfnTFgzPTBibl2= MVOyOEBp MYPpcoR2[2W|IHGgcY9l\XO2IHnuZ5Jm[XOnIHnuJGcyKHCxcIXsZZRqd25? NGT5OGIzOzRzOEWyNy=>
K008 M1PJNWFxd3C2b4Ppd{BCe3OjeR?= M2DRfVExOCCwTR?= NYXFRW1JPzJiaB?= NXPt[nJIe2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MUmyN|QyQDV{Mx?=
K028 NYDiZot{SXCxcITvd4l{KEG|c3H5 NF;KUlcyODBibl2= M33YNFczKGh? NUDJUY1te2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= NX3HcFVUOjN2MUi1NlM>
K029 MVHBdI9xfG:|aYOgRZN{[Xl? MX2xNFAhdk1? NV\zbmZlPzJiaB?= NVjFOFVVe2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= NHTae2UzOzRzOEWyNy=>
M23 NYrrZoRZSXCxcITvd4l{KEG|c3H5 M3nnRlExOCCwTR?= MUS3NkBp Mlq5d4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? M2e1RVI{PDF6NUKz
K033 MonWRZBweHSxc3nzJGF{e2G7 MV2xNFAhdk1? Mn3TO|IhcA>? MXnzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ M1fBN|I{PDF6NUKz
RD M{TFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHoblJYUUN3ME24JI5O Mn7sNlM{ODN5NEG=
Rh41 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuO2lEPTB;MUCuOEBvVQ>? NUTWb3ZHOjN|MEO3OFE>
Rh18 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTZwMjDuUS=> NXjqb4ZJOjN|MEO3OFE>
Rh30 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17qR2lEPTB;NT62JI5O NVzI[m9uOjN|MEO3OFE>
BT-12 NHO3V5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHkNnpKSzVyPUG0MlMhdk1? MVuyN|MxOzd2MR?=
CHLA-266 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi2[JVQUUN3ME2yO{4yKG6P NIPRWpEzOzNyM{e0NS=>
TC-71 NH\5W3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnRRWJKSzVyPUSuOUBvVQ>? NFPLOWgzOzNyM{e0NS=>
CHLA-9 NVryXXlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL5TWM2OD12Lk[gcm0> M1[x[VI{OzB|N{Sx
CHLA-10 M2LxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnYR5hKSzVyPUWuO{BvVQ>? MlHDNlM{ODN5NEG=
CHLA-258 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDXOWVKSzVyPU[uOEBvVQ>? MmfaNlM{ODN5NEG=
SJ-GBM2 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF{Lkmgcm0> NILTNW4zOzNyM{e0NS=>
NB-1643 NXHGVndFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTdwNDDuUS=> MkfuNlM{ODN5NEG=
NB-EBc1 NWfHcHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF4Lkigcm0> MWKyN|MxOzd2MR?=
CHLA-90 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULORWxFUUN3ME2yNk4{KG6P NEjBZZQzOzNyM{e0NS=>
CHLA-136 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDWSHlKSzVyPUKzMlIhdk1? NGn6R3MzOzNyM{e0NS=>
NALM-6 NUjYe3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFzLkegcm0> NY\QXXl2OjN|MEO3OFE>
COG-LL-317 M3rXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zWdGlEPTB;ND60JI5O Mk\6NlM{ODN5NEG=
RS4;11 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF|LkWgcm0> M3rJTlI{OzB|N{Sx
MOLT-4 NHvoSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5SGFmUUN3ME2xNE43KG6P NUnLTGF4OjN|MEO3OFE>
CCRF-CEM (1) Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf4Rm82UUN3ME2xNk42KG6P NFTwd3MzOzNyM{e0NS=>
CCRF-CEM (2) NIHFbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nhXWlEPTB;Nz6yJI5O Ml3lNlM{ODN5NEG=
Kasumi-1 NE\iWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTiWFBMUUN3ME21Mlghdk1? MXWyN|MxOzd2MR?=
Karpas-299 NYTvbJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD17Lk[gcm0> MnvsNlM{ODN5NEG=
Ramos-RA1 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTdwNDDuUS=> M3;mXlI{OzB|N{Sx
LNCaP NEn2RYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD16IH7N MX[yN|E2OjByNB?=
VCaP NFjGSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTdibl2= NG\2bIozOzF3MkCwOC=>
H1355 NUnkT5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT2OXdKSzVyPUWgcm0> MnL4NlMxOTJ{NEi=
H157 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX23V|RiUUN3ME23JI5O NVPj[GI4OjNyMUKyOFg>
H460 NGTiNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XsTGlEPTB;ODDuUS=> MUiyN|AyOjJ2OB?=
IA-LM MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPYcldKSzVyPUGwJI5O NY\3S2w4OjNyMUKyOFg>
HOP-62 NH;q[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL4TWM2OD1zMTDuUS=> NGTr[mgzOzBzMkK0PC=>
H23 NEnBcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzLWnJKSzVyPUGxJI5O MX2yN|AyOjJ2OB?=
H2030 M2TZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:ybZFKSzVyPUGyJI5O NHPaUI8zOzBzMkK0PC=>
H441 M4TmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M161dGlEPTB;MUSgcm0> NEjBcXAzOzBzMkK0PC=>
H2212 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5IH7N NX:wUYtSOjNyMUKyOFg>
SK-LU-1 NXv5O5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuxb5lKSzVyPUG4JI5O NFXaWXMzOzBzMkK0PC=>
H2009 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzETY5KSzVyPUG5JI5O NH;PNGIzOzBzMkK0PC=>
H1792 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJyIH7N MW[yN|AyOjJ2OB?=
COR-L23 M4HMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPpZZNKUUN3ME2yNkBvVQ>? M1rjXFI{ODF{MkS4
H727 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3KTWM2OD1{ODDuUS=> M4q1dFI{ODF{MkS4
H1734 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHJNJRzUUN3ME2yPEBvVQ>? MmTqNlMxOTJ{NEi=
H358 NWjRN2tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfBVIZKSzVyPUK5JI5O MYWyN|AyOjJ2OB?=
A549 NG[xWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTR|IH7N MV6yN|AyOjJ2OB?=
H2122 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\2c2lEPTB;NUOgcm0> MWGyN|AyOjJ2OB?=
Calu-1 M4TWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTV6IH7N NWC5UnRuOjNyMUKyOFg>
Calu-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL5So02UUN3ME22OEBvVQ>? NH;LZ2gzOzBzMkK0PC=>
NCI-H1975 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xOFghcA>? MWDJR|UxRTF4IH7N MV[yNlE1PDZ4NR?=
NCI-H1975 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy3NkBp MWDJR|UxRThibl2= M1fQV|IzOTR2Nk[1

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01962948 Active not recruiting Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer Fox Chase Cancer Center|National Cancer Institute (NCI) October 9 2013 Phase 1|Phase 2
NCT02012192 Terminated Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Medical University Innsbruck|European Commission July 4 2014 Phase 1|Phase 2
NCT01173523 Completed Small Cell Lung Cancer David M. Jackman MD|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute July 28 2010 Phase 2
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 Not Applicable
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID